Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 20

1.

Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder.

Durgam S, Earley W, Guo H, Li D, Németh G, Laszlovszky I, Fava M, Montgomery SA.

J Clin Psychiatry. 2016 Mar;77(3):371-8. doi: 10.4088/JCP.15m10070.

2.

The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trials.

Citrome L, Durgam S, Lu K, Ferguson P, Laszlovszky I.

J Clin Psychiatry. 2016 Jan;77(1):109-15. doi: 10.4088/JCP.15m10192.

3.

Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial.

Durgam S, Cutler AJ, Lu K, Migliore R, Ruth A, Laszlovszky I, Németh G, Meltzer HY.

J Clin Psychiatry. 2015 Dec;76(12):e1574-82. doi: 10.4088/JCP.15m09997.

4.

Cariprazine in the treatment of schizophrenia: a proof-of-concept trial.

Durgam S, Litman RE, Papadakis K, Li D, Németh G, Laszlovszky I.

Int Clin Psychopharmacol. 2016 Mar;31(2):61-8. doi: 10.1097/YIC.0000000000000110.

5.

An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression.

Durgam S, Earley W, Lipschitz A, Guo H, Laszlovszky I, Németh G, Vieta E, Calabrese JR, Yatham LN.

Am J Psychiatry. 2016 Mar 1;173(3):271-81. doi: 10.1176/appi.ajp.2015.15020164. Epub 2015 Nov 6.

PMID:
26541814
6.

Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial.

Kane JM, Zukin S, Wang Y, Lu K, Ruth A, Nagy K, Laszlovszky I, Durgam S.

J Clin Psychopharmacol. 2015 Aug;35(4):367-73. doi: 10.1097/JCP.0000000000000346.

PMID:
26075487
7.

Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study.

Calabrese JR, Keck PE Jr, Starace A, Lu K, Ruth A, Laszlovszky I, Németh G, Durgam S.

J Clin Psychiatry. 2015 Mar;76(3):284-92. doi: 10.4088/JCP.14m09081.

8.

Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial.

Sachs GS, Greenberg WM, Starace A, Lu K, Ruth A, Laszlovszky I, Németh G, Durgam S.

J Affect Disord. 2015 Mar 15;174:296-302. doi: 10.1016/j.jad.2014.11.018. Epub 2014 Nov 24.

9.

The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial.

Durgam S, Starace A, Li D, Migliore R, Ruth A, Németh G, Laszlovszky I.

Bipolar Disord. 2015 Feb;17(1):63-75. doi: 10.1111/bdi.12238. Epub 2014 Jul 24.

10.

An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial.

Durgam S, Starace A, Li D, Migliore R, Ruth A, Németh G, Laszlovszky I.

Schizophr Res. 2014 Feb;152(2-3):450-7. doi: 10.1016/j.schres.2013.11.041. Epub 2014 Jan 10.

11.

Brain uptake and distribution of the dopamine D3 /D2 receptor partial agonist [11 C]cariprazine: an in vivo positron emission tomography study in nonhuman primates.

Tóth M, Varrone A, Steiger C, Laszlovszky I, Horváth A, Kiss B, Gyertyán I, Adham N, Halldin C, Gulyás B.

Synapse. 2013 May;67(5):258-64. doi: 10.1002/syn.21631. Epub 2013 Feb 8.

PMID:
23238770
12.

Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors.

Agai-Csongor E, Domány G, Nógrádi K, Galambos J, Vágó I, Keserű GM, Greiner I, Laszlovszky I, Gere A, Schmidt E, Kiss B, Vastag M, Tihanyi K, Sághy K, Laszy J, Gyertyán I, Zájer-Balázs M, Gémesi L, Kapás M, Szombathelyi Z.

Bioorg Med Chem Lett. 2012 May 15;22(10):3437-40. doi: 10.1016/j.bmcl.2012.03.104. Epub 2012 Apr 4.

PMID:
22537450
13.

Occupancy of dopamine D₂ and D₃ and serotonin 5-HT₁A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography.

Seneca N, Finnema SJ, Laszlovszky I, Kiss B, Horváth A, Pásztor G, Kapás M, Gyertyán I, Farkas S, Innis RB, Halldin C, Gulyás B.

Psychopharmacology (Berl). 2011 Dec;218(3):579-87. doi: 10.1007/s00213-011-2343-z. Epub 2011 May 28.

14.

Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.

Kiss B, Horváth A, Némethy Z, Schmidt E, Laszlovszky I, Bugovics G, Fazekas K, Hornok K, Orosz S, Gyertyán I, Agai-Csongor E, Domány G, Tihanyi K, Adham N, Szombathelyi Z.

J Pharmacol Exp Ther. 2010 Apr;333(1):328-40. doi: 10.1124/jpet.109.160432. Epub 2010 Jan 21.

15.

Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15.

Kiss B, Laszlovszky I, Horváth A, Némethy Z, Schmidt E, Bugovics G, Fazekas K, Gyertyán I, Agai-Csongor E, Domány G, Szombathelyi Z.

Naunyn Schmiedebergs Arch Pharmacol. 2008 Nov;378(5):515-28. doi: 10.1007/s00210-008-0308-5. Epub 2008 Jun 13.

PMID:
18551280
16.

Novel sulfonamides having dual dopamine D2 and D3 receptor affinity show in vivo antipsychotic efficacy with beneficial cognitive and EPS profile.

Agai-Csongor E, Nógrádi K, Galambos J, Vágó I, Bielik A, Magdó I, Ignácz-Szendrei G, Keseru GM, Greiner I, Laszlovszky I, Schmidt E, Kiss B, Sághy K, Laszy J, Gyertyán I, Zájer-Balázs M, Gémesi L, Domány G.

Bioorg Med Chem Lett. 2007 Oct 1;17(19):5340-4. Epub 2007 Aug 15.

PMID:
17720494
17.

Effects of RGH-237 [N-{4-[4-(3-aminocarbonyl-phenyl)-piperazin-1-yl]-butyl}-4-bromo-benzamide], an orally active, selective dopamine D(3) receptor partial agonist in animal models of cocaine abuse.

Gyertyán I, Kiss B, Gál K, Laszlovszky I, Horváth A, Gémesi LI, Sághy K, Pásztor G, Zájer M, Kapás M, Csongor EA, Domány G, Tihanyi K, Szombathelyi Z.

J Pharmacol Exp Ther. 2007 Mar;320(3):1268-78. Epub 2006 Dec 14.

18.

Lack of effect of reserpine-induced dopamine depletion on the binding of the dopamine-D3 selective radioligand, [11C]RGH-1756.

Sóvágó J, Farde L, Halldin C, Schukin E, Schou M, Laszlovszky I, Kiss B, Gulyás B.

Brain Res Bull. 2005 Oct 15;67(3):219-24.

PMID:
16144658
19.

Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats.

Laszy J, Laszlovszky I, Gyertyán I.

Psychopharmacology (Berl). 2005 May;179(3):567-75. Epub 2004 Dec 24.

PMID:
15619116
20.

Positron emission tomographic evaluation of the putative dopamine-D3 receptor ligand, [11C]RGH-1756 in the monkey brain.

Sóvágó J, Farde L, Halldin C, Langer O, Laszlovszky I, Kiss B, Gulyás B.

Neurochem Int. 2004 Oct;45(5):609-17.

PMID:
15234102
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk